Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 5/20 | 0.43 |
| ▸ | PPARD | Q03181 | 10/20 | 0.39 |
| ▸ | PPARA | Q07869 | 3/20 | 0.38 |
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13508367 | 1.00 | PTGDR2 (0.43) | PTGDR2PPARDPPARAPPARGPTPN1 | |
| SCHEMBL3690133 | 0.91 | PPARD (0.46) | PTGDR2PPARDPPARAPPARGPTPN1 | |
| SCHEMBL13508255 | 0.91 | PPARD (0.46) | PTGDR2PPARDPPARAPPARGPTPN1 | |
| SCHEMBL13508266 | 0.89 | PTGDR2 (0.42) | PTGDR2PPARDPPARAPPARGPTPN1 | |
| SCHEMBL3679163 | 0.89 | PTGDR2 (0.42) | PTGDR2PPARDPPARAPPARGPTPN1 | |
| SCHEMBL14339036 | 0.89 | PTGDR2 (0.42) | PTGDR2PPARDPPARAPPARGPTPN1 | |
| SCHEMBL14338922 | 0.88 | PTGDR2 (0.42) | PTGDR2PPARDPPARAPPARGPTPN1 | |
| SCHEMBL13508273 | 0.88 | PTGDR2 (0.42) | PTGDR2PPARDPPARAPPARGPTPN1 | |
| SCHEMBL3693445 | 0.88 | PTGDR2 (0.42) | PTGDR2PPARDPPARAPPARGPTPN1 | |
| SCHEMBL14338979 | 0.88 | PTGDR2 (0.41) | PTGDR2PPARDPPARAPPARGPTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7655641-B2 | Sulfonamide derivatives as PPAR modulators | ELI LILLY AND COMPANY (US) | 2010-02-02 | — | — | US | disclosed |
| EP-1597248-B1 | SULFONAMIDE DERIVATIVES AS PPAR MODULATORS | LILLY CO ELI (US) | 2007-12-26 | — | — | EP | disclosed |
| US-20060217433-A1 | Sulfonamide derivatives as ppar modulators | ELI LILLY AND COMPANY (US) | 2006-09-28 | — | — | US | disclosed |
| EP-1597248-A2 | SULFONAMIDE DERIVATIVES AS PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-11-23 | — | — | EP | disclosed |
| WO-2004073606-A2 | SULFONAMIDE DERIVATIVES AS PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2004-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060217433-A1 | Sulfonamide derivatives as ppar modulators | PPARD, PPARA, PPARG | PTGDR2 328/4885PPARD 1/4885PPARA 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.